Abstract: A method of preparing a crystalline thin film having a formula MY2 includes (1) preparing an MYx amorphous film by atomic layer deposition on a surface of a substrate, and (2) annealing the amorphous MYx film at 350° C. or more to provide the crystalline MY2 film. The amorphous MYx film is formed from at least one metal M precursor and at least one element Y precursor, wherein x is 1.5 to 3.1, M is tungsten or molybdenum, and Y is sulfur or selenium. Step (1) includes a) introducing a first metal M precursor or element Y precursor into a deposition chamber, b) purging with inert gas, c) introducing a second metal M precursor when the first precursor is element Y, or element Y precursor when the first precursor is metal M, d) purging with inert gas, e) repeating steps a) to d), and f) obtaining the amorphous MYx film.

Abstract: An optical particle detector including at least one channel intended to receive a fluid carrying at least one particle, and across which light rays are intended to pass such that the light rays are partially scattered by the at least one particle, a plurality of photodetectors capable of receiving said scattered light rays, wherein the detector includes at least one optical waveguide configured to collect, at least at one entrance of the waveguide, light rays that were not scattered by the at least one particle and having crossed the channel, and to reinject the unscattered light rays into the channel through at least one exit of the waveguide.

Abstract: The present invention relates to a dinuclear molybdenum complex with ligands selected from fatty tertiary amines of formula (I): R—N[(CH2)nR2][(CH2)nR3]??(I) wherein R represents a linear or branched alkyl comprising 3 to 30 carbon atoms, preferably 3 to 20, advantageously 7 to 17 carbon atoms; n, identical or different, represents 2 or 3; R2 and R3, identical or different, represent an O, OR, NR?2, COOR?, or COO group, where R?, identical or different, represents a hydrogen atom or an alkaline or alkaline earth metal, preferably R? is H, preferably R2 and R3, identical or different, represent an OH or NH2 group.

Abstract: A method for modifying a cellular polymer foam with apparent porosity, which includes providing a cellular polymer foam with apparent porosity, placing the cellular polymer foam in contact with at least one compound in order to obtain a cellular polymer foam including on the surface thereof an intermediate phase formed from the compound having at least one catechol unit. The foam may be used as a catalyst substrate.

Abstract: The invention relates to an electrically insulating composite material (1) comprising a polyepoxide matrix (2) of cycloaliphatic type or of diglycidyl ether type in a content of less than 40% by mass, from 20 to 75% by mass of one or several micrometric and/or mesometric filler(s) (3), and from 0.1 to 20% by mass of at least one ionic liquid (4), the masses being expressed relative to the total mass of the electrically insulating composite material (1). The invention also relates to a method for manufacturing such an electrically insulating composite material (1), as well as its use for an electrically insulating support (9) in a metal-enclosed substation (5).

Abstract: The present invention relates to a novel pharmaceutical composition comprising doxycycline for topical application, in particular to the eye and eyelids. The invention also relates to this topical composition for use in the treatment of bacterial infections of the skin and mucous membranes.

Abstract: The present invention relates to an avian model enabling the amplification of human or animal circulating tumour cells (CTC) and to the use thereof for monitoring and determining the sensitivity of a patient or an animal suffering from cancer to one or more therapeutic agent(s), as well as for screening novel therapeutic agents intended for the treatment of cancer.

Abstract: A multilayer scintillation detector, includes at least three layers superposed on one another, and each extending parallel to a plane, called the detection plane, wherein each layer is formed by a first material, called a scintillation material, capable of interacting with an ionizing radiation and of forming, following the interaction, a scintillation light in a scintillation spectral band; each layer has a plurality of light guides, respectively extending parallel to the detection plane, according to a length, the light guides being disposed, over all or part of their length, parallel to an axis of orientation; the axis of orientation of the light guides of each layer is oriented, in the detection plane, according to an orientation, the orientations of the respective axes of orientation of at least three layers being different from one another, such that each layer has an associated orientation; and the scintillation material has a first refractive index.

Abstract: This method for acquiring a spatial map of auditory perception of a subject comprises a plurality of successive test sequences, each test sequence comprising steps of: a) calibration (1002) of the subject's position, by displaying instructions to the subject, using a head-mounted visual display system worn by the subject, in order to acquire a reference position of the subject, the subject's position being measured using a video motion capture system by measuring the spatial coordinates of a first optical marker worn by the subject, b) choosing (1004) spatial coordinates of a target location of a sound source, said target cation being located around the subject, c) emitting (1006) a predefined sound, using a sound source placed at said target location, d) in response to acquisition instructions generated by the subject using an acquisition interface, acquiring (1008) an estimated location of said sound source, by using the video motion capture system to measure the spatial coordinates of a second optical mark

Abstract: A therapy apparatus for treating tissue by the emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve (S1, S2, . . . ) with centres of curvature; centres of curvature (c1, c2, . . . ) asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry (A1) or from the axis of symmetry (S) and/or at different depths taken according to the axis of symmetry; the individual axes (a1, a2, . . . ) intersecting between the focal zones (Zc1, Zc2, . . . ) and the creation surface (8) or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone (Zr) which is off-axis relative to the plane of symmetry (A1) or to the axis of symmetry (S); the sectors of this creation surface (8) creating energy deposit zones with profiles corresponding to the focal coverage zones (Zr).

Abstract: The invention relates to an aqueous composition comprising a suspension of ZnO particles and a polymer stabiliser containing carboxylic acid functions and carboxylic acid salt functions.

Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Abstract: The invention relates to novel glycosidase substrates of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R?9, V, X, Y and Z are as defined in claim 1, and a method for detecting the presence of a catalytically active glycosidase by means of one of said substrates.

Abstract: The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).

Abstract: A power electronic module (1) including at least one semiconductor (5) that is connected to connection conductors (6, 7), and including a dielectric carrier (10) having both a fixed layer (9), on which at least one of said connection conductors (6) is mounted, and a movable layer (11), the fixed layer (9) and the movable layer (11) exhibiting similar dielectric permittivities and being superposed along at least one surface facing the at least one connection conductor (6).

Abstract: The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.

Abstract: The present invention relates to the technical field of composite materials comprising a thermosetting polymer matrix in which thermoplastic polymer and/or elastomer particles are dispersed. More precisely, the invention relates to a novel type of polymeric material obtained by using a particular ionic liquid as cross-linking agent for an epoxy resin mixed with a thermoplastic polymer and/or an elastomer. The invention also relates to a process for manufacturing said composite material and uses thereof, notably in the aeronautical, aerospace, automotive, maritime, wind power, electronics, or sports and leisure sectors.

Abstract: The invention concerns a gallinacean embryo in which cancer cells have been grafted within the embryo tissue, characterised in that the embryo is at a developmental stage between the HH10 and HH25 stages at the time of the grafting, wherein said cancer cells are not neuroblastoma cells and said cells form tumors inside the embryo.

Abstract: The present invention relates to a compound of formula (I): (I) as defined in the description. The present invention also relates to a method for extracting biological membrane-associated membrane proteins, comprising a step of bringing an aqueous solution of biological membrane-associated membrane proteins into contact with at least one compound of the invention. The present invention also relates to a method for stabilizing membrane proteins in solution in an aqueous solution, comprising a step (i) consisting in bringing an aqueous solution of a membrane protein in solution into contact with at least one compound of the invention.

Abstract: A method for detecting and quantifying additives in a complex aqueous fluid, and a method for detecting an inhibitor of mineral deposition or corrosion, injected in a gas or oil well. The invention also relates to a developer solution including a lanthanide and a chelating agent for detecting said additives or inhibitors.